3 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 3 of 3 clinical reviews.
A clinical review of Rezdiffra (resmetirom) compounding legality under FDA rules, its accelerated approval for MASH with fibrosis, prescribing label details, and post-market safety data.
A clinical and regulatory deep-dive into Rezdiffra (resmetirom) covering its accelerated FDA approval, patent portfolio, label specifications, post-market commitments, and the legal disputes shaping its commercial future.
A clinical deep-dive into resmetirom (Rezdiffra), the first FDA-approved drug for MASH-related liver fibrosis. Covers MAESTRO-NASH data, label details, safety, and the confirmatory trial pipeline.